News & views

This channel includes the latest news, interviews and opinion pieces on all aspects of regenerative medicine from around the world, aiming to keep you up to date with the field and aware of different insights and perspectives.

SCOPE Stem Cell Roundup: Mar 19

Our weekly email roundup of links via the The Stem Cell Policy and Ethics (SCOPE) program: a collaborative effort of the Johns Hopkins Berman Institute of Bioethics and the Johns Hopkins Institute for Cell Engineering.
Go to the profile of Alan Regenberg
Mar 19, 2015
Member Exclusive

Will Stem Cell Profits Measure Up?

It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative than drugs, and hence more valuable. That's the way Alain Vertès of NxR Biotechnologies sees it. In this interview with The Life Sciences Report, Vertès talks about some of the stem cell names he knows well, and draws comparisons investors can bank on.
Go to the profile of Lee Buckler
Mar 19, 2015

SCOPE Stem Cell Roundup

Our weekly email roundup of links via the The Stem Cell Policy and Ethics (SCOPE) program: a collaborative effort of the Johns Hopkins Berman Institute of Bioethics and the Johns Hopkins Institute for Cell Engineering.
Go to the profile of Alan Regenberg
Mar 16, 2015

SCOPE Stem Cell Roundup

Our weekly email roundup of links via the The Stem Cell Policy and Ethics (SCOPE) program: a collaborative effort of the Johns Hopkins Berman Institute of Bioethics and the Johns Hopkins Institute for Cell Engineering.
Go to the profile of Alan Regenberg
Mar 16, 2015